new molecules and indications for glp-1 medicines Drugs the Physiology of Metabolic Health Frontiers | The immunomodulatory effects

A smaller body may not require the same absolute muscle volume to accomplish the same tasks

Effectiveness and evidence The strongest, most reproducible evidence for weight loss comes from prescription injectable GLP-1 therapies like semaglutide and tirzepatide, with multiple large randomized trials showing significant weight reduction and metabolic benefits

And thats okay, as long as we understand how they work and what needs to happen alongside them to stay healthy

To use the Medicare GLP-1 Bridge benefit, patients generally need to meet all of the following: Be enrolled in Medicare Part D (a standalone prescription drug plan or Medicare Advantage plan with prescription drug coverage) Be at least 18 years old AND meet one of three BMI-based eligibility tiers (more restrictive than the general FDA label): Tier 1: BMI of 35 or higher (no additional conditions required), or Tier 2: BMI of 30 or higher WITH heart failure with preserved ejection fraction, OR uncontrolled hypertension (systolic blood pressure above 140 mm Hg or diastolic above 90 mm Hg despite treatment with two antihypertensive medications), OR chronic kidney disease stage 3a or above, or Tier 3: BMI of 27 or higher WITH prediabetes (per American Diabetes Association guidelines), previous myocardial infarction, previous stroke, or symptomatic peripheral artery disease Be using the medication in combination with current and ongoing lifestyle modification including structured nutrition and physical activity Have a prescription from a qualified prescriber (any licensed clinician with prescribing authority can prescribe